ScoreComparison
Why is Protalix Biotherapeutics, Inc. ?
1
With a growth in Net Sales of 4.19%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 9.92 MM
- NET SALES(HY) Higher at USD 53.65 MM
- NET PROFIT(HY) Higher at USD 22.09 MM
2
With ROE of -13.69%, it has a very attractive valuation with a 3.58 Price to Book Value
- Over the past year, while the stock has generated a return of 44.62%, its profits have fallen by -325.3%
3
High Institutional Holdings at 27.7%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 4.11% over the previous quarter.
4
Market Beating Performance
- The stock has generated a return of 44.62% in the last 1 year, much higher than market (S&P 500) returns of 15.36%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Protalix Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Protalix Biotherapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Protalix Biotherapeutics, Inc.
42.86%
1.97
63.85%
S&P 500
15.76%
1.17
13.09%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.46%
EBIT Growth (5y)
-215.21%
EBIT to Interest (avg)
-0.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.14
Tax Ratio
24.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.59%
ROCE (avg)
58.62%
ROE (avg)
6.33%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.58
EV to EBIT
-25.97
EV to EBITDA
-35.40
EV to Capital Employed
7.66
EV to Sales
2.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-29.51%
ROE (Latest)
-13.69%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 9.92 MM
NET SALES(HY)
Higher at USD 53.65 MM
NET PROFIT(HY)
Higher at USD 22.09 MM
ROCE(HY)
Highest at 31.23%
-4What is not working for the Company
INTEREST(9M)
At USD 1.07 MM has Grown at 34.59%
DEBT-EQUITY RATIO
(HY)
Highest at -45.05 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.93 times
Here's what is working for Protalix Biotherapeutics, Inc.
Net Profit
At USD 22.09 MM has Grown at 739.48%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 53.65 MM has Grown at 108.16%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 9.92 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 53.65 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD 22.09 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Here's what is not working for Protalix Biotherapeutics, Inc.
Interest
At USD 1.07 MM has Grown at 34.59%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -45.05 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 0.93 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Footer loading
